{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:12:47Z","timestamp":1784941967974,"version":"3.55.0"},"reference-count":49,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To analyse the mortality associated with intravitreal injections of bevacizumab for age\u2010related macular degeneration (<jats:styled-content style=\"fixed-case\">AMD<\/jats:styled-content>) in patients previously diagnosed with stroke or transient ischaemic attack (<jats:styled-content style=\"fixed-case\">TIA<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed bevacizumab\u2010treated <jats:styled-content style=\"fixed-case\">AMD<\/jats:styled-content> patients with a diagnosis of stroke or <jats:styled-content style=\"fixed-case\">TIA<\/jats:styled-content> prior to their first bevacizumab injection (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>948). Those patients, na\u00efve to any anti\u2010vascular endothelial growth factor (anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content>) at the time of stroke\/<jats:styled-content style=\"fixed-case\">TIA<\/jats:styled-content>, were then compared to age\u2010 and gender\u2010matched patients who had a stroke\/<jats:styled-content style=\"fixed-case\">TIA<\/jats:styled-content> at the same time and had never been exposed to anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content>. Survival analysis was performed using adjusted Cox regression. The main outcome measure was survival. Adjusted variables were age, smoking, alcohol abuse, hypertension, diabetes mellitus, obesity, ischaemic heart disease, congestive heart failure and liver cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Age and gender distribution of bevacizumab\u2010treated patients and controls were similar (mean age: 83.4 versus 83.7\u00a0years, p<jats:italic>\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.3; 51.7% males versus 52.5% males, p<jats:italic>\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.7). The adjusted mortality in patients who received bevacizumab within 3\u00a0months after stroke\/<jats:styled-content style=\"fixed-case\">TIA<\/jats:styled-content> was significantly different than in patients non\u2010exposed to bevacizumab (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\u00a0=\u00a06.92, 95%, CI 1.88\u201325.43, p<jats:italic>\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.01). Within 6\u00a0months after stroke\/<jats:styled-content style=\"fixed-case\">TIA<\/jats:styled-content>, the difference in adjusted mortality showed a strong trend (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\u00a0=\u00a02.00, 95%, CI 0.96\u20134.16, p<jats:italic>\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.064). Within 12\u00a0months, it was insignificant (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\u00a0=\u00a01.30, 95%, CI 0.75\u20132.26, p<jats:italic>\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.348).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We found increased mortality within three months after a cerebrovascular event in patients treated with bevacizumab for <jats:styled-content style=\"fixed-case\">AMD<\/jats:styled-content> compared to patients for whom there was no record of a prescription to any anti\u2010<jats:styled-content style=\"fixed-case\">VEGF<\/jats:styled-content> agent.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.13731","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T22:26:16Z","timestamp":1523917576000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mortality after a cerebrovascular event in age\u2010related macular degeneration patients treated with bevacizumab ocular injections"],"prefix":"10.1111","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0952-3740","authenticated-orcid":false,"given":"Joel","family":"Hanhart","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Shaare Zedek Medical Center Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron S.","family":"Comaneshter","sequence":"additional","affiliation":[{"name":"Central Headquarters Clalit Health Services Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Vinker","sequence":"additional","affiliation":[{"name":"Central Headquarters Clalit Health Services Tel Aviv Israel"},{"name":"Sackler School of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.11.027"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303844"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.4070"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.11.019"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305252"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.WCB.0000122745.72175.D5"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0049"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13522"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00719.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.05.024"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31825db6ba"},{"key":"e_1_2_5_13_1","first-page":"516921","article-title":"Fellow eye macular edema improvement after intravitreal bevacizumab for radiation retinopathy","volume":"2015","author":"Brito IA","year":"2015","journal-title":"Case Rep Ophthalmol Med"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1994.tb04426.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02240.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61501-9"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1385\/MN:23:2-3:121"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.10.1097"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70274-0"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)22010-6"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774512438980"},{"key":"e_1_2_5_22_1","first-page":"115","article-title":"Implication of bevacizumab in fatal arterial thromboembolic incidents","volume":"14","author":"Grivas AA","year":"2009","journal-title":"J BUON"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.94"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4857"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000156"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.11.019"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.019"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31822c28d6"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.112.654632"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.400"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2003.11.069"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381096"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2155-4"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.040"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-308077"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.156810"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.02.007"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000209260"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841860903524396"},{"key":"e_1_2_5_40_1","first-page":"404","article-title":"Prevalence of selected chronic diseases in Israel","volume":"3","author":"Rennert G","year":"2001","journal-title":"Isr Med Assoc J"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-011-9552-5"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6718-9"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200216666151001120831"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.002"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317977"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.2333"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2009.02.003"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13501"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302451"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102484"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faos.13731","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.13731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T21:15:07Z","timestamp":1694294107000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.13731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,16]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1111\/aos.13731"],"URL":"https:\/\/doi.org\/10.1111\/aos.13731","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,16]]},"assertion":[{"value":"2017-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}